Anticancer agents that inhibit tumor growth by targeting a cell-cycle regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas. The research suggests that CDK4 inhibitors, which are now in clinical testing, should be used cautiously, particularly in patients with B-cell lymphomas. The findings raise the possibility that these inhibitors work through off-target effects and require further investigation.